
David Augustus Fiellin MD
Addiction Medicine
Professor, Internal Medicine, Emergency Medicine, Public Health, Yale School of Medicine Vice Chief, Faculty Affairs, General Internal Medicine Director, Program in Addiction Medicine
Join to View Full Profile
789 Howard AveYnhhNew Haven, CT 06519
Phone+1 203-688-2471
Fax+1 203-688-4516
Dr. Fiellin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1994
- Emory University School of MedicineClass of 1991
Certifications & Licensure
- CT State Medical License 1994 - 2026
- American Board of Preventive Medicine Addiction Medicine
Clinical Trials
- Buprenorphine and Integrated HIV Care Evaluation Start of enrollment: 2005 Aug 01
- Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Start of enrollment: 2008 Jul 01
- Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol). Start of enrollment: 2011 May 01
- Join now to see all
Publications & Presentations
PubMed
- Intervention for hospitalized people with chronic pain and elevated risk for opioid-related harm: A pilot randomized controlled trial.Melissa B Weimer, Michele J Buonora, Alexandra M Hajduk, Adam L Ackerman, Krishna R Daggula
Journal of Hospital Medicine. 2025-04-24 - Hospital-Initiated Naltrexone for Alcohol Use Disorder.Melissa B Weimer, David A Fiellin
JAMA Internal Medicine. 2025-04-21 - Impact of an electronically-integrated clinical pathway on hospital initiation of medications for alcohol use disorder and subsequent hospital utilization.Kelsey O Cole, Melissa B Weimer, Kaicheng Wang, David A Fiellin, Anisha J Advani
Journal of Hospital Medicine. 2025-04-13
Journal Articles
- Racial Disparities in Discontinuation of Long-Term Opioid Therapy Following Illicit Drug Use Among Black and White PatientsDavid A Fiellin, William C Becker, Drug and Alcohol Dependence
- Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled TrialStephen R Holt, Michael Virata, David A Fiellin, E Jennifer Edelman, Lynn E Fiellin, AIDS and Behavior
- Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving HealthcareE Jennifer Edelman, Derek D Satre, David A Fiellin, Adam J Gordon, Katharine A Bradley, AIDS and Behavior
- Join now to see all
Authored Content
- Toward Better Stewardship: Gaining Control over Controlled SubstancesMay 2018
- Toward Better Stewardship: Gaining Control over Controlled SubstancesMay 2018
Press Mentions
- Oral and Injectable Naltrexone Similarly Effective for Alcohol Use DisorderApril 21st, 2025
- Why Do so Few U.S. Psych Hospitals Use Medications for Opioid Use Disorder?November 14th, 2024
- More Doctors Can Now Prescribe a Key Opioid Treatment. Will It Help?March 3rd, 2023
- Join now to see all
Grant Support
- Integrated Stepped Care For Unhealthy Alcohol Use In HIVNational Institute On Alcohol Abuse And Alcoholism2011
- Models Of Sbirt For Opioid Dependent Patients In The Emergency DepartmentNational Institute On Drug Abuse2008–2011
- Buprenorphine Maintenance Vs. Detoxification In Prescription Opioid DependenceNational Institute On Drug Abuse2007–2011
- Counseling For Primary Care Office-Based BuprenorphineNational Institute On Drug Abuse2005–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: